M Sutherland
Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder
Sutherland, M; Gill, J.H; Loadman, P.M; Laye, J.P; Sheldrake, H.M; Illingworth, N.A; Alandas, M.N; Cooper, P.A; Searcey, M; Pors, K; Shnyder, S.D; Patterson, L.H
Authors
J.H Gill
P.M Loadman
J.P Laye
H.M Sheldrake
N.A Illingworth
M.N Alandas
P.A Cooper
M Searcey
K Pors
S.D Shnyder
L.H Patterson
Abstract
We identify cytochrome P450 1A1 (CYP1A1) as a target for tumor-selective drug development in bladder cancer and describe the characterization of ICT2700, designed to be metabolized from a prodrug to a potent cytotoxin selectively by CYP1A1. Elevated CYP1A1 expression was demonstrated in human bladder cancer relative to normal human tissues. RT112 bladder cancer cells, endogenously expressing CYP1A1, were selectively chemosensitive to ICT2700, whereas EJ138 bladder cells which do not express CYP1A1 were significantly less responsive. Introduction of CYP1A1 into EJ138 cells resulted in 75-fold increased chemosensitivity to ICT2700 relative to wild-type EJ138. Negligible chemosensitivity was observed to ICT2700 in EJ138 cells expressing CYP1A2, or with exposure of EJ138 cells to CYP1B1 or CYP3A4 generated metabolites of ICT2700. Chemosensitivity to ICT2700 was also negated in EJ138-CYP1A1 cells by the CYP1 inhibitor α-naphthoflavone. Furthermore, ICT2700 did not induce expression of the AhR-regulated CYP1 family indicating that constitutive CYP1A1 expression is sufficient for activation of ICT2700. Consistent with the selective activity by CYP1A1 was a time and concentration dependent increase in γ-H2AX protein expression, indicative of DNA damage, associated with the activation of ICT2700 in RT112 but not EJ138 cells. In mice bearing CYP1A1 positive and negative isogenic tumors, ICT2700 administration resulted in an antitumor response only in the CYP1A1 expressing tumor model. This antitumor response was associated with detection of the CYP1A1-activated metabolite in tumors but not in the liver. Our findings support the further development of ICT2700 as a tumor-selective treatment for human bladder cancers.
Citation
Sutherland, M., Gill, J., Loadman, P., Laye, J., Sheldrake, H., Illingworth, N., …Patterson, L. (2013). Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Molecular Cancer Therapeutics, 12(1), 27-37. https://doi.org/10.1158/1535-7163.mct-12-0405
Journal Article Type | Article |
---|---|
Publication Date | Jan 1, 2013 |
Deposit Date | Dec 21, 2012 |
Journal | Molecular Cancer Therapeutics |
Print ISSN | 1535-7163 |
Electronic ISSN | 1538-8514 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 12 |
Issue | 1 |
Pages | 27-37 |
DOI | https://doi.org/10.1158/1535-7163.mct-12-0405 |
You might also like
Rationalized Computer-Aided design of Matrix Metalloprotease-Selective Prodrugs
(2017)
Journal Article
Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors
(2016)
Journal Article
Oncology Activity
(2016)
Book Chapter
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search